Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 22 member B5 (SVOPL) (SVOPL)
- Target
- SVOPL
- Molecular classification
- Transporter (solute carrier family), Vesicular protein, Major Facilitator Superfamily (MFS) member
01
Overview
Solute carrier family 22 member B5 (SVOPL) is a protein-coding gene that encodes a vesicular protein most similar to SVOP, and is part of the SLC22B subfamily of solute carriers. It is distant from classical organic cation/anion/zwitterion transporters in the SLC22A subfamily, but shares homology with synaptic vesicle glycoproteins (SV2). SVOPL displays a canonical 12-transmembrane domain architecture characteristic of the major facilitator superfamily (MFS) transporters. Its precise physiological substrate(s) and direct function are unknown, and it remains classified as an orphan transporter. Expression is detected in various tissues, with notable upregulation in pancreatic ductal adenocarcinoma linked to worse clinical prognosis, suggesting its potential as a novel therapeutic target in cancer. There are currently no drugs, known endogenous ligands, or mechanistic studies specific to SVOPL, and validated disease biomarkers or safety considerations have not been established.
- Other names
- SVOP likeSVOPLSLC22B5Putative transporter SVOPLSV2-related protein-likeSVOP-like proteinsolute carrier family 22 member B5MGC46715SV2 related protein homolog-like
02
Mechanism of action
Unknown—no characterized mechanism, ligands, or pharmacological modulators have been assigned to SVOPL
03
Biological functions
Putative vesicular transporter activityInvolved in processes related to synaptic or secretory vesicle functionCorrelated with cell signaling in cancer (e.g., EMT, TNF-α signaling, and angiogenesis in pancreatic cancer)
04
Disease associations
Cancer, particularly associated with pancreatic ductal adenocarcinoma (PDAC)Neurodegenerative disease (implicated along with SV2/SVOP family, but less clear for SVOPL specifically)Other (potential roles in synaptic physiology due to homology, but not well-defined)
Beyond the preview
Go deeper on Solute carrier family 22 member B5 (SVOPL) (SVOPL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier family 22 member B5 (SVOPL) (SVOPL).